Antengene (FRA:722) Beginning Cash Position: €85.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:722 Antengene Corp Ltd FRA:722
40 GF Score
Price €0.41
GF Value €0.15
! 5 Warning Signs
View Full Analysis

What is Antengene Beginning Cash Position?

Antengene FRA:722 +0.98% 40 Beginning Cash Position is €85.28 Mil as of Dec. 2025. GuruFocus rates FRA:722 with a GF Score™ of 40/100 and a GF Value™ of €0.15. The stock has 5 warning signs investors should review.

Antengene's Beginning Cash Position for the quarter that ended in Dec. 2025 was €85.28 Mil.

Antengene's quarterly Beginning Cash Position increased from Dec. 2024 (€61.41 Mil) to Jun. 2025 (€88.39 Mil) but then declined from Jun. 2025 (€88.39 Mil) to Dec. 2025 (€85.28 Mil).

Antengene's annual Beginning Cash Position increased from Dec. 2023 (€77.80 Mil) to Dec. 2024 (€86.88 Mil) and increased from Dec. 2024 (€86.88 Mil) to Dec. 2025 (€88.76 Mil).

Antengene Beginning Cash Position Related Terms

Antengene Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Antengene's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antengene Beginning Cash Position Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 291.00 177.95 77.80 86.88 88.76

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 115.24 84.82 61.41 88.39 85.28
FRA:722
40GF Score
Antengene Corp Ltd FRA:722
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antengene Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €85.28 Mil mean?
Antengene (FRA:722) has a Beginning Cash Position of €85.28 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Antengene and its competitors.
Is Antengene's Beginning Cash Position too high?
Antengene's current Beginning Cash Position is €85.28 Mil. Overall, Antengene has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Antengene's Beginning Cash Position compare to VRTX and REGN?
Antengene's Beginning Cash Position of €85.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Antengene and its competitors. Antengene's current Beginning Cash Position is €85.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antengene stock overvalued right now?
Antengene (FRA:722) has a current Beginning Cash Position of €85.28 Mil. The stock's GF Value™ is €0.15, compared to a current price of €0.41 — trading 176% above its estimated fair value. The current Beginning Cash Position is €85.28 Mil. Antengene's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Antengene (FRA:722), the current Beginning Cash Position is €85.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Antengene (FRA:722) Overvalued in 2026?

Based on GuruFocus' analysis, Antengene stock appears to be overvalued. The current stock price of €0.41 is trading 176% above its estimated GF Value™ of €0.15.

Key valuation signals for FRA:722:

  • Beginning Cash Position: €85.28 Mil
  • GF Value™: €0.15 vs. price of €0.41 (176% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the FRA:722 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Antengene Business Description

Other Exchanges 06996:Hong Kong
Address 1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
40GF Score

Get the complete analysis for FRA:722

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.41
Price
€0.15
GF Value